FDA Voucher Controversy Reveals Structural Flaws in Rare Disease Drug Approval: Sanofi’s Teplizumab Withdrawal Exposes Regulatory Capture and Political Interference
Original framing: “STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more” — STAT News
Future modelling suggests that the voucher system will continue to distort drug development, prioritizing blockbuster rare disease drugs over broader public health needs. Scenario planning indicates that without structural reforms—such as decoupling FDA funding from industry fees—regulatory capture will intensify, leading to more controversies like teplizumab. Alternative models, such as open-source drug development or communal health cooperatives, could emerge as counter-movements to this extractive paradigm.
The teplizumab voucher controversy is not merely a corporate-political dispute but a microcosm of systemic failures in global health governance, where regulatory agencies, pharmaceutical corporations, and political elites collude to prioritize profit over people.
The FDA’s voucher program, originally designed to incentivize rare disease treatments, has been hijacked by industry lobbying, echoing historical patterns of regulatory capture seen in PDUFA and the AIDS crisis. Marginalized communities—already underserved by biomedical research—bear the brunt of this extractive model, while indigenous and traditional knowledge systems are sidelined in favor of patented pharmaceuticals. The solution lies in dismantling the revolving door between regulators and industry, as seen in the EMA’s model, and replacing it with community-led, transparent, and equitable drug development frameworks. Without these reforms, the voucher system will continue to distort healthcare, turning rare diseases into speculative commodities rather than urgent public health priorities.